Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA.
Department of Surgery, Division of Thoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
Clin Lung Cancer. 2019 Jan;20(1):e63-e71. doi: 10.1016/j.cllc.2018.09.004. Epub 2018 Sep 20.
Stereotactic body radiation therapy (SBRT) is standard for medically inoperable stage I non-small-cell lung cancer (NSCLC) and is emerging as a surgical alternative in operable patients. However, limited long-term outcomes data exist, particularly according to operability. We hypothesized long-term local control (LC) and cancer-specific survival (CSS) would not differ by fractionation schedule, tumor size or location, or operability status, but overall survival (OS) would be higher for operable patients.
All consecutive patients with stage I (cT1-2aN0M0) NSCLC treated with SBRT from June 2009 to July 2013 were assessed. Thoracic surgeon evaluation determined operability. Local failure was defined as growth following initial tumor shrinkage or progression on consecutive scans. LC, CSS, and OS were calculated using Cox proportional hazards regression.
A total of 186 patients (204 lesions) were analyzed. Most patients were inoperable (82%) with Eastern Cooperative Oncology Group performance status of 1 (59%) or 2 (26%). All lesions received biological effective doses ≥ 100 Gy most commonly (94%) in 3 to 5 fractions. The median follow-up was 4.0 years. LC at 2 and 5 years were 95.6% (95% confidence interval, 92%-99%) and 93.7% (95% confidence interval, 90%-98%), respectively. Compared with operable patients, inoperable patients did not have significant differences in 5-year LC (93.1% vs. 96.7%; P = .49), nodal failure (31.4% vs. 11.0%; P = .12), distant failure (12.2% vs. 10.4%; P = .98), or CSS (80.6% vs. 91.0%; P = .45) but trended towards worse OS (34.2% vs. 45.3%; P = .068). Tumor size, location, and fractionation did not significantly influence outcomes.
SBRT has excellent, durable LC and CSS rates for early-stage NSCLC, although inoperable patients had somewhat lower OS than operable patients, likely owing to greater comorbidities.
立体定向体部放射治疗(SBRT)是无法手术的 I 期非小细胞肺癌(NSCLC)的标准治疗方法,并且正在成为可手术患者的手术替代方法。然而,目前尚缺乏长期结果数据,特别是根据可操作性。我们假设,根据分割方案、肿瘤大小或位置以及可操作性,局部控制(LC)和癌症特异性生存(CSS)不会有差异,但可手术患者的总生存(OS)会更高。
评估了 2009 年 6 月至 2013 年 7 月期间接受 SBRT 治疗的所有 I 期(cT1-2aN0M0)NSCLC 连续患者。胸外科医生的评估确定了可操作性。局部失败定义为初始肿瘤缩小后或连续扫描时的进展。使用 Cox 比例风险回归计算 LC、CSS 和 OS。
共分析了 186 例患者(204 个病灶)。大多数患者(82%)为不可手术,东部合作肿瘤组的表现状态为 1(59%)或 2(26%)。所有病变的生物有效剂量均≥100Gy,最常见的是 3 至 5 个剂量。中位随访时间为 4.0 年。2 年和 5 年时的 LC 分别为 95.6%(95%置信区间,92%-99%)和 93.7%(95%置信区间,90%-98%)。与可手术患者相比,不可手术患者 5 年 LC 无显著差异(93.1%比 96.7%;P=0.49)、淋巴结失败(31.4%比 11.0%;P=0.12)、远处失败(12.2%比 10.4%;P=0.98)或 CSS(80.6%比 91.0%;P=0.45),但 OS 略差(34.2%比 45.3%;P=0.068)。肿瘤大小、位置和分割方式并未显著影响结果。
SBRT 对早期 NSCLC 具有出色、持久的 LC 和 CSS 率,尽管不可手术患者的 OS 略低于可手术患者,但可能是由于合并症更多。